AQP2 and heart failure: Schrier et al. [13] showed that mozavaptan, a non-peptide AVP V2 receptor antagonist, suppressed AQP2 mRNA expression and water retention in an experimental model of heart failure in rats with ligated coronary arteries, suggesting that non-peptide AVP V2 receptor antagonists may effectively treat patients with heart failure.